Skip to main content

Table 3 Effect of HBV and HCV co-infections on ART attrition among HIV patients who initiated ART between 2010 and 2018 in Guangxi, China

From: Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study

Variables Number of HIV patients Attritions Person-years (PY) Attrition rate per 100 person-years (95% CI) HR (95% CI) P value aHRa (95% CI) P value
Total 58,239 13,872 234,421.19 5.92 (5.82–6.01)     
HIV 46,847 10,169 187,680.8 5.42 (5.32–5.52) Reference   Reference  
HIV + HBV 6,707 1,442 28,092.09 5.13 (4.87–5.39) 0.95 (0.90–1.01) 0.074 1.34 (1.27–1.42)  < 0.001
HIV + HCV 3,828 1,823 15,148.30 12.03 (11.50–12.57) 2.22 (2.11–2.33)  < 0.001 1.73 (1.61–1.87)  < 0.001
HIV + HBV + HCV 857 438 3500.00 12.51 (11.37–13.66) 2.31 (2.10–2.54)  < 0.001 2.07 (1.85–2.31)  < 0.001
  1. CI, Confidence interval; HR, Hazard ratio; aHR, Adjusted hazard ratio; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HIV, Human immunodeficiency virus
  2. aAdjusted for Age, gender, marital status, route of HIV transmission, CD4 count before ART, WHO clinical stage before ART, initial first-line ART regimen, current ART regimen, duration of using TDF-containing regimens, calendar year of ART initiation